Over the course of this year there have been some pivotal studies on osteoporosis and women's health. We've published stories based on studies that explore the use of vitamin D and calcium supplementation and bone mineral density. We've featured a few studies that examine the effectiveness of bisphosphonates and the role of anabolic agents to to fight osteoporosis. Learn more about these and other studies in today's slideshow.
Beta Blockers May Protect Against Bone Loss: Beta blockers may slow the rate of bone loss that occurs as people age, a study published in JBMR Plus suggests.
Asthma Inhalers May Be Linked to Increased Risk of Osteoporosis: Use of either oral or inhaled corticosteroids to manage asthma can increase the risk of osteoporosis and fragility fractures, suggest the findings of a large study published in Thorax.
Individualized Approach Needed for Bisphosphonate Use in Women: In women 50 years of age or older, the risk of atypical femur fracture increased with longer bisphosphonate use, Asian ancestry, shorter height, higher weight and glucocorticoid use for one year or more, but this risk rapidly decreased after bisphosphonate discontinuation, according to a study recently published in New England Journal of Medicine.
Bisphosphonate Use Associated with Increased Fracture Risk:
Bisphosphonate use, especially for more than five years, is associated with an increased risk of atypical femoral fractures, but this risk falls considerably after discontinuation, according to a Nationwide Danish an analysis and review presented on September 13 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held virtually.
Zoledronate As Booster Drug in Fight Against Osteoporosis: Some evidence shows the combination of teriparatide and denosumab, followed by a single dose of zoledronate, may be an effective strategy in the long-term management of high-risk fragility fractures.
High-Intensity Activity in Adolescence May Help Prevent Osteoporosis: Spending more time in high-intensity physical activity in early life may protect against osteoporosis in later life, and men are more successful at this than women, according to a study recently published in JAMA Network Open.
Q&A: Vitamin D and Bone Mineral Density: High-dose vitamin D supplementation compared with standard-dose vitamin D supplementation resulted in a greater loss of volumetric bone mineral density in women but not men, according to study data presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.
Q&A: Anabolic Agents for Osteoporosis: Three months of treatment with the osteoporosis drug abaloparatide (Tymlos, Radius) has a robust effect on bone formation in postmenopausal women with osteoporosis, according to a study presented on Sept. 12 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which is being held virtually.
Atypical Bone Fracture Risk Rises With Bisphosphonates: Atypical femur fracture risks are very low, but the risk rises with long-term use of bisphosphonate, study says.
Bisphosphonates Lower Fracture Risk, but Not Mortality: Mortality rates after a bone fracture can be as high as 45% in the first year of a break, and while bisphosphonates can lower the risk of recurring fractures, it doesn't appear to lower the risk of death.
Podcast: Are your patients well verse on vitamin D intake?
Managing vitamin D levels may not be as straightforward as it would seem. There are factors that should be considered that are not often communicated to patients. In today's edition of Overdrive, the Rheumatology Network podcast, we talk with Dr. Suzanne Jan de Beur of Johns Hopkins University School of Medicine. She serves as director of endocrinology at Johns Hopkins Bayview Medical Center and president-elect of the American Society for Bone and Mineral Research.